• Home
  • About
  • Clinical
  • Authors
  • Most read this year
  • GP Opinion
  • Videos & Podcasts
  • Professional
  • Comments policy
  • RACGP
  • poll
Menu

Filter
Semaglutide unavailable in Australia until April 2023

Semaglutide unavailable in Australia until April 2023

GPs have been told not to initiate any new patients on either semaglutide or dulaglutide, which will also only have ‘limited availability’.


What GPs need to know about GLP-1 RAs

What GPs need to know about GLP-1 RAs

SPONSORED: The medication has been described as a ‘paradigm shift’ in the way type 2 diabetes is managed.


New breast cancer research has ‘immediate implications’

New breast cancer research has ‘immediate implications’

The study has produced fresh evidence about the use of androgens as a potential treatment for oestrogen receptor-positive breast cancer.


Popular hypertension drug linked with suicide

Popular hypertension drug linked with suicide

Angiotensin receptor blockers may be associated with a higher risk of suicide than alternative medications, a new study has found.


Old doc, new disease: Anti-NMDA receptor encephalitis

Old doc, new disease: Anti-NMDA receptor encephalitis

Dr Casey Parker reflects on an intriguing presentation that made him ask: What else do I not know?


  • Previous
  • 1
  • 2
  • Next
Pages: 2 of 2
RACGP newsGP ArticlesnewsGP

Terms and conditions | Privacy statement | RACGP | recruitGP | AJGP

© 2018 The Royal Australian College of General Practitioners (RACGP) ABN 34 000 223 807